Respiratory Syncytial Virus (RSV) - A market yet to reach its full potential

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.


Scope

  • Discusses disease background, providing insight in RSV epidemiology, etiology and symptoms
  • Gives a breakdown of RSV (hospitalization) prevalence in the seven major markets
  • Examines current diagnosis and treatment trends, providing physicians' opinions
  • Examines the RSV pipeline by type treatment, prophylaxis and vaccines, including a short discussion of each pipeline product


    • Report Highlights
    Some physicians do not value the importance of a correct RSV diagnosis, since there is no effective treatment available. Furthermore, the American Academy of Pediatrics does not recommend routine testing for RSV in bronchiolitis. However, there are reasons why proper diagnosis should be considered, and there is a range of tests available for that.

    The RSV market is currently dominated by MedImmune's Synagis, a prophylactic monoclonal antibody. As RespiGam's successor, Synagis was first launched in 1998 and now has sales of around $750 million per RSV season. Due to its high costs though, Synagis is only prescribed to a very limited group of individuals.

    Although the most important unmet need in RSV is an effective treatment or vaccine, many companies have discontinued their developments in this field. Only two companies have an RSV treatment in clinical development (Novartis/Arrow Therapeutics and Alnylam) and MedImmune dominates the limited vaccine development.


    Reasons to Purchase

  • Gain insight into the issues of current diagnosis and treatment for RSV through key opinion leader comments
  • Review the unmet needs and the clinical and commercial factors driving new product decisions
  • Identify the opportunities and threats presented by the RSV pipeline and predict the future shape of the market

    • Table of Contents

    Other users found this report page using the following search terms: rsv Respiratory Syncytial Virus rsv market vaccine respiratory syncytial virus prevalence numax treatment bronchiolitis

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.